6:52 PM
 | 
May 24, 2007
 |  BC Extra  |  Company News

BioMarin submits Kuvan NDA

BioMarin (BMRN; SWX:BMRN) submitted an NDA to FDA for Kuvan sapropterin (formerly Phenoptin) to treat phenylketonuria (PKU). The...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >